Skip to main content
SpringerLink
Log in

Anidulafungin: profile report

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Murdoch D, Plosker GL. Anidulafungin. Drugs 2004; 64(19): 2249–58

    Article  PubMed  CAS  Google Scholar 

  2. Steinbach WJ. Anidulafungin: a viewpoint. Drugs 2004; 64(19): 2259

    Article  Google Scholar 

  3. Vazquez JA. Anidulafungin: a viewpoint. Drugs 2004; 64(19): 2259–60

    Article  Google Scholar 

  4. Vazquez JA. Invasive oesophageal candidiasis: current and developing treatment options. Drugs 2003; 63(10): 971–89

    Article  PubMed  CAS  Google Scholar 

  5. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000 Apr; 30(4): 653–7

    Article  PubMed  CAS  Google Scholar 

  6. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362(9390): 1142–51

    Article  PubMed  CAS  Google Scholar 

  7. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770–5

    Article  PubMed  CAS  Google Scholar 

  8. Brown GL, White RJ, Turik M. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis [abstract no. 1106]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

  9. Krause DS, Reinhardt J, Vazquez A, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agent Chemother 2004 Jun; 48(6): 2021–4

    Article  CAS  Google Scholar 

  10. Vicuron Pharmaceuticals Inc. Vicuron Pharmaceuticals announces phase III results of anidulafungin combination regimen for treatment of invasive aspergillosis [online]. Available from URL: http://www.vicuron.com [Accessed 2004 May 5]

  11. Vazquez J, Schranz J, Krause D, et al. Efficacy results from a phase 2/3 study of anidulafungin in patients with azole-refractory mucosal candidiasis [abstract no. M-1038]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington, DC

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anidulafungin: profile report. Drugs Ther. Perspect 21, 4–5 (2005). https://doi.org/10.2165/00042310-200521040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521040-00002

Search

Navigation